Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen.

导出 LinkOut

翻译打印收藏纠错

作者： Su-In,Kim ^[1] ; Sung-Hoon,Jung ^[1] ; Ho-Young,Yhim ^[2] ; Jae-Cheol,Jo ^[3] ; Ga-Young,Song ^[1] ; Mihee,Kim ^[1] ; Seo-Yeon,Ahn ^[1] ; Jae-Sook,Ahn ^[1] ; Deok-Hwan,Yang ^[1] ; Hyeoung-Joon,Kim ^[1] ; Je-Jung,Lee ^[1]

作者单位： Department of Hematology-Oncology, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, Hwasun, Korea. ^[1] Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea. ^[2] Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. ^[3]

关键词 Early infection Levofloxacin Multiple myeloma Prophylaxis

DOI 10.5045/br.2021.2021176

PMID 35197371

发布时间 2022-05-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood research

2022年57卷1期

51-58页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen.

Blood research

相似文献

Blood research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen.

Blood research

相似文献

Blood research

相关期刊

检索历史清除